OpenAI Foundation Commits $100M to AI-Powered Hepatitis C Elimination

The OpenAI Foundation made its first major foray into public health on August 13, 2026, announcing a $100 million commitment to the Common Health Coalition for a new initiative called Breakthroughs to Follow-Through. The program’s opening salvo is an ambitious goal: use artificial intelligence to at least double hepatitis C cure rates across eight U.S. jurisdictions over the next two years.

A Cure That Already Exists

The cruel irony of hepatitis C is that the medical problem has already been solved. Oral direct-acting antiviral medications can cure more than 95% of HCV infections in just eight to twelve weeks. There is no lengthy treatment regimen, no complex surgical intervention — just a course of pills with a near-perfect success rate. Yet roughly two out of every three Americans living with hepatitis C remain undiagnosed, untreated, or lost to follow-up care. The bottleneck is not pharmacological. It is operational.

An estimated 2.4 million adults in the United States are living with chronic hepatitis C, and thousands more are infected each year. Left untreated, the virus quietly damages the liver over decades, leading to cirrhosis, liver cancer, and death. The Centers for Disease Control and Prevention has called HCV elimination a national priority, and Congress passed the Cure Hepatitis C Act to expand access to screening and treatment. But the gap between policy and clinical reality remains vast, particularly for uninsured and underinsured populations who fall through the cracks of a fragmented healthcare system.

What AI Brings to the Table

This is where the OpenAI Foundation believes artificial intelligence can make a difference. The Breakthroughs to Follow-Through initiative will deploy AI tools across several specific operational bottlenecks:

Case finding and screening. AI systems will analyze electronic health records, lab data, and claims data to identify patients who have been tested for HCV but never linked to treatment, as well as those at high risk who have never been screened. This automated case-finding approach mirrors techniques already used in population health management but with greater scale and precision.

Patient record synthesis. One of the biggest barriers to HCV treatment is data fragmentation. A patient may be tested at a community clinic, receive lab results at a hospital, and seek care at a different provider entirely. AI tools will synthesize records across these silos, giving care teams a unified view of each patient’s status.

Administrative automation. Prior authorization, insurance verification, appointment scheduling, and referral management consume enormous amounts of clinical staff time. The initiative will use AI to automate these workflows, freeing nurses and care coordinators to focus on direct patient engagement.

Patient navigation and outreach. AI-assisted outreach will track patients across the care continuum, sending reminders, answering questions, and flagging individuals who have dropped out of the treatment pipeline for re-engagement.

The Eight-State Rollout

The initiative will begin in eight states: Alabama, Illinois, Louisiana, Massachusetts, and four additional jurisdictions to be named as the program scales. These states were selected based on HCV burden, the strength of existing public health infrastructure, and the presence of partner organizations on the ground. The Common Health Coalition — a collaboration spanning clinician groups, health departments, hospitals, payers, and community organizations — will coordinate implementation, while the OpenAI Foundation provides both funding and technical expertise.

The goal of doubling cure rates within two years is deliberately aggressive. If successful, it would represent one of the most rapid public health scale-ups in recent U.S. history and would provide a replicable model for other conditions.

A Broader Vision

The hepatitis C initiative is the first concrete project under the OpenAI Foundation’s new AI for Civil Society and Philanthropy program, announced simultaneously. Anna Makanju, who joined the Foundation four months ago after a tenure at OpenAI focused on public policy, is helping shape the program’s direction. In a LinkedIn post, Makanju described Breakthroughs to Follow-Through as building “the infrastructure patients need to actually get life-saving medical advances” while giving practitioners “the tools to reach more patients with proven treatments.”

The Foundation has signaled that hepatitis C is only the beginning. The initiative is designed with extensibility in mind, with plans to expand the model to other curable conditions including HIV and certain cancers. The broader goal aligns with the OpenAI Foundation’s March 2026 announcement of at least $1 billion in investments across life sciences, economic opportunity, AI resilience, and community programs — itself part of a $25 billion long-term commitment to health and curing diseases.

Why This Matters

The announcement is significant for several reasons. First, it represents one of the largest single investments in applying frontier AI to public health delivery in the United States. While AI has been widely discussed in healthcare contexts — from radiology to drug discovery — most applications have focused on clinical decision support or research. Breakthroughs to Follow-Through targets the unglamorous but critical domain of care coordination, where the gap between what medicine can do and what actually reaches patients is widest.

Second, the initiative arrives at a moment when hepatitis C elimination is politically and economically viable. The CDC has estimated that providing curative treatment to all Americans with HCV could save billions in downstream medical costs. The treatment exists. The funding exists. What has been missing is the infrastructure to connect patients to care at scale — exactly the kind of infrastructure AI is well-suited to build.

Third, the program offers a test case for whether philanthropic AI investment can drive measurable public health outcomes. If the OpenAI Foundation can demonstrate that AI tools meaningfully improve cure rates in real-world settings, it could reshape how both governments and private funders think about the role of technology in healthcare delivery.

Challenges Ahead

The road will not be easy. Healthcare data interoperability remains a stubborn problem, with electronic health record systems that often cannot communicate across institutions. Privacy regulations like HIPAA add layers of compliance complexity to any data-driven initiative. And the populations most affected by hepatitis C — including people who inject drugs, incarcerated individuals, and those experiencing homelessness — are among the hardest to reach through traditional care delivery models.

The Common Health Coalition’s multi-stakeholder structure is designed to address these challenges by bringing together all the actors needed to close care gaps: clinicians who provide treatment, payers who cover it, health departments that track disease, and community organizations that reach marginalized populations. Whether AI can live up to its promised role as the connective tissue between these actors will be the defining question of the initiative’s first two years.

What is clear is that the OpenAI Foundation is putting real money — $100 million of it — behind the proposition that artificial intelligence can do more than generate text and images. It can help cure a disease that has been curable for years, if only the system could find the patients who need treatment and guide them through to completion. The next two years will tell us whether that proposition holds.